The largest and the most diverse real-world study of SPINRAZA® in
adults with SMA published!
The Lancet Neurology publication adds to the growing body of published evidence
demonstrating the clinical benefit of SPINRAZA® specifically in adults.
SPINRAZA® is indicated for all patients with 5q‑associated
SMA1
The SPINRAZA® clinical trial programme included 346 patients aged from
newborns to young adults with SMA who received SPINRAZA® for up to 5 years1
The largest and the most diverse real-world study of SPINRAZA® in
adults with SMA published!
The Lancet Neurology publication adds to the growing body of published evidence demonstrating the clinical benefit of SPINRAZA® specifically in adults.
WATCH THE VIDEO TO DISCOVER MORE ABOUT SPINRAZA®
Explore SPINRAZA® highlights
Mechanism of action
SPINRAZA® has a well-defined, targeted mechanism of action that increases
production of full-length, functional SMN protein in the central nervous system1
Clinical resources
Exclusive clinical resources including latest SPINRAZA® data, motor function
measures, videos, and a treatment scheduling tool
SPINRAZA® patients
Discover real SPINRAZA® patients and learn about the Together in SMA patient
support programme
Clinical resources
Exclusive clinical resources including latest SPINRAZA® data, motor function
measures, videos, and a treatment scheduling tool